Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allakos Inc.

0.3291
0.0000
Volume:- -
Turnover:238.63K
Market Cap:29.74M
PE:-0.41
High:0.3291
Open:0.3291
Low:0.3291
Close:0.3291
52wk High:1.56
52wk Low:0.2157
Shares:90.38M
Float Shares:51.98M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7938
EPS(LYR):-1.3044
ROE:-88.87%
ROA:-52.64%
PB:0.54
PE(LYR):-0.25

Loading ...

Company Profile

Company Name:
Allakos Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.